Change in Certifying Accountants (Form 8-K)

(a) Dismissal of Independent Registered Public Accounting Firm

On August 21, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of Inhibikase Therapeutics, Inc. (the "Company") approved the dismissal of CohnReznick LLP ("CohnReznick") as the Company's independent registered public accounting firm, effective immediately.

The audit reports of CohnReznick on the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through the date of CohnReznick's dismissal there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) between the Company and CohnReznick on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of CohnReznick, would have caused CohnReznick to make reference thereto in its report on the Company's consolidated financial statements.

During the fiscal year ended December 31, 2024, CohnReznick advised the Company that a material weakness existed in the Company's internal control over financial reporting, which constituted a reportable event as defined in Item 304(a)(1)(v) of Regulation S-K. The material weakness was previously disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and was subsequently remediated by prior management of the Company, as disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

Other than the reportable event described in the immediately preceding paragraph, there were no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K) during the fiscal years ended December 31, 2025 and 2024 and the subsequent interim periods through the date of CohnReznick's dismissal.

The Company provided CohnReznick with a copy of the disclosures contained in this Current Report on Form 8-K and requested that CohnReznick furnish the Company with a letter addressed to the Securities and Exchange Commission (the "SEC") stating whether it agrees with the statements made herein, and if not, stating the respects in which it does not agree. A copy of CohnReznick's letter, dated August 26, 2026, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On August 21, 2026, the Audit Committee appointed Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with such appointment effective immediately following the dismissal of CohnReznick.

During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through the date of this Current Report, neither the Company nor anyone acting on its behalf consulted with Deloitte regarding: